Providing independent clinical excellence since 2005
Insulin resistance often develops silently for years before diabetes or heart disease appears. Discover how modern metabolic assessment, including body composition, visceral fat analysis and targeted blood testing, can identify early risk, allowing personalised lifestyle and medical strategies to restore metabolic health, improve energy, and reduce long-term cardiovascular risk.
Sedentary work creates dangerous visceral fat that actively promotes cardiovascular disease through inflammatory pathways and insulin resistance. Prolonged sitting suppresses crucial enzymes and disrupts metabolism in ways that cannot be fully offset by exercise alone, requiring targeted workplace interventions.
Modern lipid management requires both substantial percentage LDL reduction and achieving low absolute LDL levels. Relative reduction reflects treatment intensity, while absolute LDL determines residual risk. Trials consistently show “lower is better.” Even with good percentage drops, patients may remain undertreated—making combined pharmacological and lifestyle strategies essential to reduce atherogenic exposure and cardiovascular risk.
Traditional upper limits for ALT (often ≤55 U/L in UK labs) were derived decades ago, before the epidemic of obesity and steatosis. Current evidence suggests these ranges are too high — and that values above 30 U/L may already indicate liver injury in people with metabolic risk. The British Society of Gastroenterology (BSG) guidelines emphasise that a result within the “normal range” may not be reassuring if the patient is metabolically high-risk
The Eight-Month Metabolic Reset is a structured cardiometabolic programme designed to reduce visceral fat, preserve skeletal muscle strength, and improve glucose stability. Combining lifestyle change, targeted metabolic support, and clinical guidance, it helps break the cardiometabolic cycle and build sustainable long-term health beyond short-term weight loss.
By Juliette Martin, Nutritional Therapist: Over the past year, a family of medications called GLP-1 agonists, often referred to as the ‘skinny jab’ has captured widespread media attention.